BioCentury
ARTICLE | Politics & Policy

FDA extends window for off-label discussion

December 15, 2016 1:21 AM UTC

FDA will extend the window for stakeholders to comment on issues related to off-label communications concerning FDA-approved medical products. The agency will now accept comments until April 10, 2017, extending the comment period by 90 days...